Latest News

  • All
  • ATAI Life Sciences
  • BetterLife Pharma
  • Braxia Scientific
  • Bright Minds Biosciences
  • Champignon Brands
  • Compass Pathways
  • Core One Labs
  • Cybin Inc
  • Entheon Biomedical
  • Field Trip Health
  • Havn Life
  • MindMed
  • Mindset Pharma
  • Mydecine Innovations Group
  • Numinus Wellness
  • Revive Therapeutics
  • Silo Pharma
  • Silo Wellness
  • Small Pharma
  • Tryp Therapeutics

Cybin Awards Grant for Psychedelic Treatment Clinic at Lenox Hill Hospital to Benefit Underserved Communities

November 23, 2021
Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced it has awarded a grant for ...

COMPASS Pathways granted fifth US patent for crystalline psilocybin

November 23, 2021
COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that ...

Revive Therapeutics Files for FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation

November 23, 2021
TORONTO, Nov. 23, 2021 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused ...

Silo Pharma and Strategic Partner Zylo Therapeutics Begin Development Process for Novel Ketamine Loaded Z-Pods

November 18, 2021
Englewood Cliffs NJ, Nov. 18, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as ...

Mydecine Reports Third Quarter 2021 Financial Results and Provides Business Update

November 16, 2021
To Launch Phase 2/3 Smoking Cessation Clinical Trial with Johns Hopkins University (JHU) Signed 5-Year Research Agreement with JHU to Further Mydecine’s Research of Multiple ...

Small Pharma Strengthens Board With Appointment of Paul Maier as Independent Director

November 16, 2021
LONDON, Nov. 18, 2021 (GLOBE NEWSWIRE) — Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted ...

Newsletter

Sign up for the latest news and info direct from Psychedelic Europe

Follow us on social media

Facebook Twitter Linkedin Youtube

Privacy Policy ♦ Terms and Conditions 

All rights reserved – Psychedelic Europe 2021

Designed and built by Stellium